A 62-year-old woman with extensive-stage small cell lung cancer has completed 4 cycles of cisplatin + etoposide with a partial response. She now presents with progressive disease 6 months after completing first-line chemotherapy. Which agent is the drug of choice for second-line therapy in this patient?

Explanation

## Second-Line Therapy for Relapsed Small Cell Lung Cancer **Key Point:** Topotecan is the FDA-approved and guideline-recommended drug of choice for second-line treatment of SCLC with recurrence ≥3 months after first-line platinum-etoposide therapy. ### Mechanism of Action - **Topotecan**: Topoisomerase I inhibitor (distinct from etoposide's topoisomerase II inhibition) - Stabilizes topoisomerase I–DNA complex, prevents DNA religation - Induces apoptosis in rapidly dividing cells ### Evidence for Topotecan in Relapsed SCLC | Parameter | Topotecan | Docetaxel | Pemetrexed | Gemcitabine | |-----------|-----------|-----------|------------|-------------| | **FDA Approval** | Yes (SCLC relapse) | No (SCLC) | No (SCLC) | No (SCLC) | | **RCT Evidence** | Hryniuk trial (OS benefit) | Limited in SCLC | Limited in SCLC | Limited in SCLC | | **Response Rate** | 20–35% (relapsed) | 10–20% | 10–15% | 10–15% | | **Standard of Care** | Yes (NCCN, ESMO) | Off-label only | Off-label only | Off-label only | | **Timing** | Sensitive relapse (≥3 mo) | Any relapse | Any relapse | Any relapse | **High-Yield:** Topotecan is classified as a **camptothecin derivative** — a class distinct from platinum agents and etoposide. This non-cross-resistant mechanism makes it ideal for platinum-refractory disease. **Clinical Pearl:** - **Sensitive relapse** (recurrence >3 months after first-line): Topotecan or re-challenge with cisplatin + etoposide are options; topotecan preferred if etoposide toxicity was significant. - **Refractory relapse** (<3 months): Topotecan is still considered, though prognosis is poor; clinical trial enrollment is encouraged [cite:Harrison 21e Ch 101]. ### Classification of SCLC Relapse ```mermaid flowchart TD A[SCLC Recurrence After First-Line PE]:::outcome --> B{Time to Relapse?}:::decision B -->|≥ 3 months| C[Sensitive Relapse]:::outcome B -->|< 3 months| D[Refractory Relapse]:::outcome C --> E[Topotecan or Re-challenge PE]:::action D --> F[Topotecan or Clinical Trial]:::action E --> G[Assess Response]:::outcome F --> G ``` **Mnemonic:** **TOPO-RELAPSE** = **TOPO**tecan for SCLC **RELAPSE** (second-line standard).